Stockholm, Sweden – October 31, 2025 — Immedica Pharma has announced that its New Drug Submission (NDS) for Loargys® (pegzilarginase) has been accepted for review by Health Canada, marking the company’s first regulatory filing in Canada. The submission has been granted priority review, underscoring the therapy’s potential to address arginase 1 deficiency (ARG1-D), a rare urea cycle disorder with significant unmet need.
Science Significance
Loargys® is a recombinant human enzyme therapy designed to rapidly and sustainably lower plasma arginine and its toxic metabolites, addressing the underlying metabolic defect in ARG1-D. Patients with this rare disorder accumulate arginine, leading to spasticity, seizures, developmental delays, and early mortality. By targeting the root cause rather than managing symptoms alone, Loargys® represents a disease-modifying treatment option in a field that currently has none approved. The mechanism highlights precision enzyme replacement for a genetically defined metabolic pathway, expanding the frontier of rare-disease biotherapeutics.
Regulatory Significance
The acceptance of the NDS by Health Canada and granting of priority review are pivotal regulatory milestones for Immedica. Priority review indicates that Loargys® meets criteria for significant unmet medical need and could lead to an accelerated decision timeline. This step enhances alignment with other global regulatory authorities and positions the therapy for potential expedited review. For Immedica, it underscores readiness of its regulatory submission and strengthens its regulatory strategy across international jurisdictions.
Business Significance
Advertisement
This submission marks a notable advancement in Immedica’s commercialisation strategy for rare metabolic disorders. As the company targets a global market with a rare-disease indication, the Canadian filing expands its geographic footprint and underscores its ambition in specialty care. The move also signals potential for licensing deals, market access agreements, and investor interest in the rare-disease segment, which commands premium pricing and strong market differentiation. By advancing Loargys® toward approval, Immedica enhances its pipeline value and strategic positioning.
Patients’ Significance
For patients living with ARG1-D — often diagnosed in infancy or childhood with limited therapeutic options — the development of Loargys® offers new hope. A therapy that addresses the metabolic root cause can significantly improve clinical outcomes, reduce toxic arginine burden, and potentially improve neurological function, quality of life, and life expectancy. The filing in Canada brings this potential closer for patients there and signals global progress toward wider access.
Policy Significance
The development of Loargys® aligns with public-health policy priorities that emphasise rare disease innovation, patient access to novel therapies, and global regulatory harmonisation. Priority review status reflects growing regulatory focus on accelerating therapies for underserved conditions. Additionally, rare-disease focus emphasises the need for health-system readiness to adopt high-impact therapies and optimise reimbursement frameworks to support access.
Immedica Pharma’s submission of the NDS for Loargys® in Canada represents a strategic and scientific milestone in the treatment of ARG1-D. By targeting the metabolic defect with a novel enzyme therapy, the company advances from pre-clinical promise to regulatory reality, bridging science and patient impact. As the review progresses, the potential approval of Loargys® could redefine the standard of care for this rare disorder and strengthen Immedica’s standing as a global rare-disease biopharma innovator.
Source: Immedica Pharma press release
